Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

LRMR

Live52w high -44.2%

Annual Quarterly

Core line items from LRMR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: LARIMAR THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2020 2020-03-31	Annual 2019 2019-12-31	Annual 2019 2019-09-30	Annual 2019 2019-06-30
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-6.67M	$-23.21M	$-17.06M	$-8.43M
Net Income	Not available	$-6.67M	$-23.13M	$-17.06M	$-3.70M
EPS (Diluted)	$-0.42	Not available	Not available	Not available	Not available
Total Assets	Not available	$73.70M	$5.20M	$92.89M	$103.88M
Total Liabilities	Not available	$22.96M	$5.89M	$33.01M	$31.75M
Cash & Equivalents	Not available	$38.98M	$1.01M	$43.34M	$37.24M
Free Cash Flow OCF − CapEx	Not available	$-8.98M	$-22.78M	$-14.82M	$-9.00M
Shares Outstanding	Not available	37.47M	6.09M	37.37M	37.33M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from LRMR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -44.2%

Entity: LARIMAR THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2020 2020-03-31	Annual 2019 2019-12-31	Annual 2019 2019-09-30	Annual 2019 2019-06-30
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-6.67M	$-23.21M	$-17.06M	$-8.43M
Net Income	Not available	$-6.67M	$-23.13M	$-17.06M	$-3.70M
EPS (Diluted)	$-0.42	Not available	Not available	Not available	Not available
Total Assets	Not available	$73.70M	$5.20M	$92.89M	$103.88M
Total Liabilities	Not available	$22.96M	$5.89M	$33.01M	$31.75M
Cash & Equivalents	Not available	$38.98M	$1.01M	$43.34M	$37.24M
Free Cash Flow OCF − CapEx	Not available	$-8.98M	$-22.78M	$-14.82M	$-9.00M
Shares Outstanding	Not available	37.47M	6.09M	37.37M	37.33M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.